Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States

Daratumumab (DARA) is an anti-CD38 monoclonal antibody approved as a combination therapy for newly diagnosed multiple myeloma (MM) and as monotherapy and combination therapy for relapsed or refractory MM cases. We assessed the length of DARA use across lines of therapy and the probabilities of treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonseca, Rafael, Chinaeke, Eric E., Gupta-Werner, Niodita, Fu, Alex Z., Kaila, Shuchita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507479/
https://www.ncbi.nlm.nih.gov/pubmed/37731678
http://dx.doi.org/10.1016/j.mayocpiqo.2023.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507479/
https://www.ncbi.nlm.nih.gov/pubmed/37731678
http://dx.doi.org/10.1016/j.mayocpiqo.2023.07.001

Ejemplares similares